ANVS
Annovis Bio, Inc.
NYSE · Healthcare · Biotechnology · US
$1.21
+11.01%Nov 4, 2026, 21:07 UTC
Annovis Bio announced a proposed underwritten public offering of common stock or pre-funded warrants, together with accompanying warrants.
Source:Oct 30, 2026, 21:00 UTC
Annovis Bio received a notice from the New York Stock Exchange that it no longer complies with continued listing standards because its average market capitalization over 30 consecutive trading days and its stockholders’ equity were each below $50 million.
Source:Oct 22, 2026, 12:00 UTC
Annovis Bio announced that it will attend and present at the 19th Annovis Bio, Inc. conference in Boston on November 16–19, 2026.
Source:Sep 23, 2026, 12:00 UTC
Annovis Bio announced a collaboration with Weave Bio, an AI regulatory content and knowledge management platform, to support its planned New Drug Application for buntanetap in Alzheimer's disease.
Aug 25, 2026, 12:05 UTC
ANNOVIS BIO announced that its Phase 3 clinical trial for Alzheimer's disease has completed enrollment of all subjects, with key data and regulatory submission expected in 2027.
Source:Aug 14, 2026, 12:00 UTC
Annovis Bio, Inc. reported its financial results for the second quarter ended June 30, 2026.
Source:Jul 7, 2026, 11:00 UTC
Annovis Bio reached full enrollment in its pivotal Phase 3 trial of buntanetap for early Alzheimer's disease.
Source: